The Syreon Corporation (“Syreon”) was established in 1995 at the University of British Columbia for the purpose of combining medical, pharmaceutical, statistical and information sciences to conduct international health care research. Syreon now provides a full suite of research services in personalized medicine, prospective clinical studies, health economics / outcomes research, and disease management support across a broad range of therapeutic areas in more than 40 countries around the world.
Syreon partners primarily with leading global pharmaceutical corporations, emerging biotechnology companies and academic networks to identify therapeutic trends, streamline new drug investigation, monitor clinical use, define economic value, and control development costs in a broad range of acute and chronic disorders in today's competitive and challenging environment.
From its head offices in North America and Europe, Syreon links with over 1,000 scientists and investigators in institutions and clinics across North and Latin America, Europe and Russia, the Middle East and Africa, Asia and Australia creating highly flexible research networks that are rapidly scalable to include from 40 to 40,000 subjects in the study of acute and chronic diseases.
Syreon proprietary ClinStream™ electronic clinical research system links these key partners in the research process with speed, security and accuracy, independent of time or geographic location. It enables a seamless integration of genomic, laboratory, clinical, health outcomes and economic data for real-time analysis and forecasting, and is ideally adapted to the fast pace of modern drug evaluation.
Syreon Research Romania
Syreon Research Romania (SRR) was established in 2013.
The activity of the company in Romania is led by Dr. László Lorenzovici and is supported by a team of multidisciplinary specialists with extensive knowledge on the healthcare sector in Romania and other Central and Eastern European countries.
SRR carries out and coordinates a wide range of health economic analyses for acute and chronic diseases. Resource use is being monitored and data is collected from patients and healthcare providers as well as from analysts and consultants, in order to elaborate detailed and unique cost vectors for various disease indications. Also medical outcomes are collected to measure the burden of disease, treatment consequences and cost-effectiveness of interventions.
SRR scientists have long standing experience with the hospital and pharmaceutical industry, especially concerning developing and maintaining administrative health care databases.
Dr. László Lorenzovici
CEO of Syreon Research Romania